| Name | Title | Contact Details |
|---|
Neovia benefits from a multi-activities, multi-species and multi-areas experience. It is a reference in terms of innovative solutions in breeding.
The West Virginia Health Information Network (WVHIN) offers services that enable the secure electronic exchange of patient health information, providing benefits to health care providers, health care systems and patients. In February 2010, the West Virginia Department of Health and Human Resources received $7.8 million in federal funds as part of the State Health Information Exchange Cooperative Agreement Program. The West Virginia Health Information Network (WVHIN) is using these funds to launch WVHIN’s statewide electronic health information exchange services. In August 2011, the WVHIN chose Truven Health Analytics as its technical services partner. Together with Truven Health and its strategic partners, the WVHIN has made the electronic exchange of patient health information a reality for health care providers and patients across the State of West Virginia.
Lourdes Nursing Home is a Waterford, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.